Anthony Boutros El-Khoueiry, MD

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
AddressNOR 3440, NTT
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 3900
vCardDownload vCard
    Other Positions
    Title(s)Norris Cancer Center CISO Chair

    Title(s)USC NCCC Clinical Trials Network

    Title(s)Section Chief for Developmental Therapeutics in the Division of Medical Oncology


    Collapse Biography 
    Collapse Awards and Honors
    USC1998Dean's Scholar
    Division of Hematology2003Researcher of the Year
    Southwest Oncology Group2004Young Investigator Training Award
    National Cancer Institute 2011  - 2012Clinical Investigator Team Leadership Award
    University of California, IrvineGolden Key National Honor Society

    Collapse Overview 
    Collapse Overview
    Anthony El-Khoueiry, MD, is an assistant professor of clinical medicine at the Keck School of Medicine of USC and director of clinical translation at the Southern California Clinical and Translational Science Institute (SC CTSI). He has extensive experience in clinical and translational research through his roles as medical director of the Clinical Investigations Support Office and director of the phase I drug development program at the USC Norris Comprehensive Cancer Center. He is the recipient of the National Cancer Institute Cancer Investigator Team Leadership Award in 2011.

    Dr. El-Khoueiry has established a national reputation in clinical research-related hepatobiliary (liver, gall bladder and bile duct) and pancreatic cancers. He is a member of the National Cancer Institute Hepatobiliary Cancers Task Force and chair of the Southwest Oncology Group hepatobiliary cancers subcommittee. In addition, he is the principal investigator of several phase I, including first-in-human, clinical trials aimed at developing novel therapies for solid tumors. Dr. El-Khoueiry works with several basic scientists at USC on joint translational projects designed to identify molecular predictors of outcome and survival for patients with advanced gastrointestinal cancers.

    Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at USC. He unravels scientific and non-scientific mysteries in four languages: English, Arabic, French and Spanish.

    Collapse Research 
    Collapse Research Activities and Funding
    Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
    NIH U01AA027681Sep 25, 2018 - Aug 31, 2023
    Role: Co-Principal Investigator
    NCTN - Network Lead Academic Participating Site: USC
    NIH UG1CA180830Apr 17, 2014 - Feb 28, 2025
    Role: Co-Principal Investigator
    NCI NCTN- Network Lead Academic Participating Site: USC
    NIH U10CA180830Apr 17, 2014 - Feb 28, 2019
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. CCALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma. Cancer Res Commun. 2024 Feb 16. Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, Huang B, Tang YW, Wen Y, Schwartz LH, El-Khoueiry AB, Knox JJ, Rajdev L, Bertagnolli MM, Meyerhardt JA, O'Reilly EM, Venook AP. PMID: 38363156.
      View in: PubMed   Mentions: Translation:HumansCellsCTClinical Trials
    2. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2023 Dec 25. El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B. PMID: 38151184.
      View in: PubMed   Mentions: 1     Fields:    
    3. Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). Clin Transl Sci. 2023 08; 16(8):1445-1457. Sangro B, Yau T, El-Khoueiry AB, Kudo M, Shen Y, Tschaika M, Roy A, Feng Y, Gao L, Aras U. PMID: 37165980; PMCID: PMC10432868.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    4. Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. Br J Cancer. 2023 08; 129(2):309-317. El-Khoueiry AB, Clarke J, Neff T, Crossman T, Ratia N, Rathi C, Noto P, Tarkar A, Garrido-Laguna I, Calvo E, Rodón J, Tran B, O'Dwyer PJ, Cuker A, Abdul Razak AR. PMID: 37237172; PMCID: PMC10338470.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    5. Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor-Initiating Stem-Like Cells. Adv Sci (Weinh). 2023 05; 10(14):e2206812. Chen CL, Hernandez JC, Uthaya Kumar DB, Machida T, Tahara SM, El-Khoueiry A, Li M, Punj V, Swaminathan SK, Kirtane A, Chen Y, Panyam J, Machida K. PMID: 36949364; PMCID: PMC10190641.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    6. Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers: Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809). Ann Surg Oncol. 2023 Mar; 30(3):1354-1363. Gholami S, Colby S, Horowitz DP, Guthrie KA, Ben-Josef E, El-Khoueiry AB, Blanke CD, Philip PA, Kachnic LA, Ahmad SA, Rocha FG. PMID: 36622529; PMCID: PMC10695673.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    7. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol. 2023 01 01; 9(1):102-111. McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. PMID: 36480191; PMCID: PMC9857666.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    8. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. J Clin Oncol. 2023 03 20; 41(9):1747-1757. Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F. PMID: 36512738; PMCID: PMC10022845.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    9. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022 Dec; 23(12):1558-1570. Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. PMID: 36400106.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    10. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer. 2022 10; 10(10). Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. PMID: 36302562; PMCID: PMC9621185.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    11. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. Cancer Lett. 2022 11 01; 548:215899. Zhang L, Li HT, Shereda R, Lu Q, Weisenberger DJ, O'Connell C, Machida K, An W, Lenz HJ, El-Khoueiry A, Jones PA, Liu M, Liang G. PMID: 36087682; PMCID: PMC9563073.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    12. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022 04; 3(4):386-401. Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. PMID: 35484418; PMCID: PMC9060366.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    13. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. Eur J Cancer. 2022 06; 168:91-98. Freemantle N, Mollon P, Meyer T, Cheng AL, El-Khoueiry AB, Kelley RK, Baron AD, Benzaghou F, Mangeshkar M, Abou-Alfa GK. PMID: 35487183.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    14. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer. 2022 Apr 09; 22(1):377. El-Khoueiry AB, Meyer T, Cheng AL, Rimassa L, Sen S, Milwee S, Kelley RK, Abou-Alfa GK. PMID: 35397508; PMCID: PMC8994237.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    15. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 01; 23(1):77-90. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. PMID: 34914889.
      View in: PubMed   Mentions: 323     Fields:    Translation:HumansCTClinical Trials
    16. Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer. 2022 Jan; 11(1):38-47. Rimassa L, Kelley RK, Meyer T, Ryoo BY, Merle P, Park JW, Blanc JF, Lim HY, Tran A, Chan YW, McAdam P, Wang E, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. PMID: 35222506; PMCID: PMC8820164.
      View in: PubMed   Mentions: 21  
    17. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. PMID: 34554208; PMCID: PMC8461552.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    18. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer. 2022 03; 126(4):569-575. Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK. PMID: 34621044; PMCID: PMC8854685.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    19. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res. 2022 01 01; 28(1):71-83. Diab A, Hamid O, Thompson JA, Ros W, Eskens FALM, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, Wang X, Joh T, Liao K, Salek-Ardakani S, Taylor CT, Chou J, El-Khoueiry AB. PMID: 34615725.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    20. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021 09; 9(9). Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. PMID: 34518290; PMCID: PMC8438858.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    21. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. PMID: 34358484.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCTClinical Trials
    22. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol. 2021; 13:17588359211036544. Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. PMID: 34377158; PMCID: PMC8326820.
      View in: PubMed   Mentions: 15  
    23. Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemother Pharmacol. 2021 11; 88(5):825-836. Akce M, El-Khoueiry A, Piha-Paul SA, Bacque E, Pan P, Zhang ZY, Ewesuedo R, Gupta D, Tang Y, Milton A, Zajic S, Judson PL, O'Bryant CL. PMID: 34324028; PMCID: PMC8484145.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    24. Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. Cancers (Basel). 2021 Jul 12; 13(14). Barzi A, Zhou K, Wang S, Dodge JL, El-Khoueiry A, Setiawan VW. PMID: 34298690; PMCID: PMC8305188.
      View in: PubMed   Mentions: 8  
    25. Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2021 08 15; 27(16):4521-4530. Johnson M, El-Khoueiry A, Hafez N, Lakhani N, Mamdani H, Rodon J, Sanborn RE, Garcia-Corbacho J, Boni V, Stroh M, Hannah AL, Wang S, Castro H, Spira A. PMID: 34083236.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    26. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021 09; 75(3):600-609. Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B. PMID: 34051329.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    27. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021 Jul; 98:102221. El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. PMID: 34029957.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    28. Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer. 2021 Jun; 10(3):240-248. Vogel A, Rimassa L, Sun HC, Abou-Alfa GK, El-Khoueiry A, Pinato DJ, Sanchez Alvarez J, Daigl M, Orfanos P, Leibfried M, Blanchet Zumofen MH, Gaillard VE, Merle P. PMID: 34239810; PMCID: PMC8237801.
      View in: PubMed   Mentions: 23  
    29. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 04; 87(4):525-532. Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. PMID: 33423090; PMCID: PMC8058950.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    30. Liver Cancer Immunity. Hepatology. 2021 01; 73 Suppl 1:86-103. Rizvi S, Wang J, El-Khoueiry AB. PMID: 32516437; PMCID: PMC8218340.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    31. Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectr. 2021 02; 5(1). Zhou K, Pickering TA, Gainey CS, Cockburn M, Stern MC, Liu L, Unger JB, El-Khoueiry AB, Terrault NA. PMID: 33442663; PMCID: PMC7791625.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):e204564. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. PMID: 33001135; PMCID: PMC7530824.
      View in: PubMed   Mentions: 465     Fields:    Translation:HumansCTClinical Trials
    33. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020 12 01; 26(23):6158-6167. Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG. PMID: 32878766.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    34. Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. Oncologist. 2020 12; 25(12):e1879-e1885. Barzi A, Choi A, Tsao-Wei D, Iqbal S, El-Khoueiry A, Agafitei DR, Cologne KG, Lenz HJ. PMID: 32649004; PMCID: PMC8186403.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    35. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020 08; 5(4). Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. PMID: 32847838; PMCID: PMC7451459.
      View in: PubMed   Mentions: 30  Translation:Humans
    36. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020 12; 73(6):1460-1469. Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A. PMID: 32710922; PMCID: PMC7751218.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansCTClinical Trials
    37. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020 09 15; 26(18):4795-4804. Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. PMID: 32636319; PMCID: PMC7779341.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    38. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. PMID: 32416072; PMCID: PMC7523268.
      View in: PubMed   Mentions: 322     Fields:    Translation:HumansCTClinical Trials
    39. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer. 2020 05; 130:219-227. Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster H. PMID: 32234665; PMCID: PMC7539324.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    40. Atezolizumab and Bevacizumab Combination Therapy for Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2020 Mar; 16(3):145-148. El-Khoueiry A. PMID: 34035716; PMCID: PMC8132702.
      View in: PubMed   Mentions: 1  
    41. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020 02; 72(2):320-341. Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. PMID: 31954495; PMCID: PMC7779342.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    42. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019 Nov 01; 5(11):1582-1588. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. PMID: 31486832; PMCID: PMC6735405.
      View in: PubMed   Mentions: 60     Fields:    
    43. Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials. Front Oncol. 2019; 9:968. Cheng JH, Tiulim JW, Zhou S, El-Khoueiry A, Nieva J. PMID: 31681560; PMCID: PMC6813196.
      View in: PubMed   Mentions: 4  
    44. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 04 20; 37(12):1015-1027. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. PMID: 30856044.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    45. Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology. 2018 10; 68(4):1412-1428. Liu M, Zhang L, Li H, Hinoue T, Zhou W, Ohtani H, El-Khoueiry A, Daniels J, O'Connell C, Dorff TB, Lu Q, Weisenberger DJ, Liang G. PMID: 29774579; PMCID: PMC6173644.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    46. Monitoring Twitter Conversations for Targeted Recruitment in Cancer Trials in Los Angeles County: Protocol for a Mixed-Methods Pilot Study. JMIR Res Protoc. 2018 Sep 25; 7(9):e177. Reuter K, Angyan P, Le N, MacLennan A, Cole S, Bluthenthal RN, Lane CJ, El-Khoueiry AB, Buchanan TA. PMID: 30274964; PMCID: PMC6231794.
      View in: PubMed   Mentions: 7  
    47. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 05; 379(1):54-63. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. PMID: 29972759; PMCID: PMC7523244.
      View in: PubMed   Mentions: 955     Fields:    Translation:HumansCTClinical Trials
    48. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology. 2018; 94(6):329-339. Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A. PMID: 29719302; PMCID: PMC7725004.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    49. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Invest New Drugs. 2018 12; 36(6):1026-1036. Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, Chen T, Zhu L, Poojary S, Basak S, Qi Z, Spreafico A, Fischer BS, Desai J. PMID: 29637471; PMCID: PMC7523345.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    50. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 05; 81(5):957-963. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. PMID: 29520435; PMCID: PMC6330274.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    51. Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 2018 04; 81(4):659-670. El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF. PMID: 29468455; PMCID: PMC7539325.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    52. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018 10; 36(5):836-847. King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua SY, Messersmith WA, El-Khoueiry AB. PMID: 29333575; PMCID: PMC7519583.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    53. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. PMID: 29182496; PMCID: PMC6075847.
      View in: PubMed   Mentions: 265     Fields:    Translation:HumansCTClinical Trials
    54. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. PMID: 28632865; PMCID: PMC5545896.
      View in: PubMed   Mentions: 382     Fields:    Translation:Humans
    55. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget. 2017 May 23; 8(21):35326-35338. Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. PMID: 28186961; PMCID: PMC5471058.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsCTClinical Trials
    56. AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol. 2017 Jul 10; 35(20):2251-2259. Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. PMID: 28489509; PMCID: PMC5501365.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCells
    57. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24; 389(10088):2492-2502. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. PMID: 28434648; PMCID: PMC7539326.
      View in: PubMed   Mentions: 1889     Fields:    Translation:HumansCTClinical Trials
    58. The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book. 2017; 37:311-317. El-Khoueiry A. PMID: 28561676; PMCID: PMC7539323.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    59. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. Pharmacogenomics J. 2018 01; 18(1):29-34. Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, El-Khoueiry A, Lenz HJ. PMID: 27503579; PMCID: PMC7505126.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    60. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clin Cancer Res. 2016 05 15; 22(10):2368-76. Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. PMID: 26644411; PMCID: PMC7519584.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    61. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol. 2015 Nov; 9(9):1799-814. Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N. PMID: 26160429; PMCID: PMC5528722.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    62. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015 Aug 20; 33(24):2617-22. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. PMID: 25964250; PMCID: PMC4534524.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansCTClinical Trials
    63. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer. 2015 Mar; 4(2):115-25. Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS. PMID: 26020033; PMCID: PMC4439789.
      View in: PubMed   Mentions: 9  
    64. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar; 75(3):537-46. Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. PMID: 25567350; PMCID: PMC4344391.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    65. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. Pharmacogenomics J. 2015 Jun; 15(3):226-34. Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ. PMID: 25487679.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    66. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015 03 01; 21(5):1044-51. Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB. PMID: 25388167.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    67. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. PMID: 25374407.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    68. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. PMID: 25349975; PMCID: PMC4264453.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    69. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb; 33(1):241-6. Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman C. PMID: 25318437.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    70. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis. Cancer. 2014 Dec 01; 120(23):3707-16. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. PMID: 25081299; PMCID: PMC9191612.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    71. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014 Feb 18; 110(4):882-7. El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. PMID: 24423918; PMCID: PMC3929880.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCellsCTClinical Trials
    72. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. Cancer Chemother Pharmacol. 2013 Jul; 72(1):53-64. El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E. PMID: 23719718.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    73. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15; 19(4):920-8. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. PMID: 23362325.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    74. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs. 2013 Aug; 31(4):845-57. Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. PMID: 23299388.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    75. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 2013 Apr; 13(2):173-80. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ. PMID: 22231565; PMCID: PMC3326190.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    76. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jun; 23(6):1455-64. Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ. PMID: 21989330; PMCID: PMC3360546.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    77. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 01; 17(21):6934-43. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. PMID: 21918173.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    78. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5783-92. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. PMID: 21791631; PMCID: PMC3174848.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    79. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1646-51. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. PMID: 21748296; PMCID: PMC3490705.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    80. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011 Jun 28; 105(1):44-52. Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS. PMID: 21629245; PMCID: PMC3137402.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    81. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602. Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. PMID: 21556747; PMCID: PMC3519425.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    82. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011 May 15; 71(10):3635-48. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. PMID: 21464044; PMCID: PMC3118510.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    83. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 2012 Jun; 30(3):1175-83. El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ. PMID: 21424698; PMCID: PMC3745766.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    84. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. PMID: 20142723.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    85. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. PMID: 20062993.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    86. Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S28-36. Zhu AX, El-Khoueiry A, Llovet JM. PMID: 20011562; PMCID: PMC2791389.
      View in: PubMed   Mentions: 2  
    87. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010 Jan; 21(1):78-86. Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ. PMID: 19622587; PMCID: PMC2795613.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    88. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer. 2008 Dec 15; 113(12):3279-89. Etzioni DA, El-Khoueiry AB, Beart RW. PMID: 18951522.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    89. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008 Dec 01; 14(23):7884-95. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. PMID: 19047118.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    90. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 2008 Apr 15; 68(8):3037-42. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18413774.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    91. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18192902.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    92. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007 Dec; 8(12):1705-13. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ. PMID: 18086000.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    93. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007 Aug 20; 25(24):3726-31. Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, El-Khoueiry A, Iqbal S, Sherrod AE, Lurje G, Lenz HJ. PMID: 17704422.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    94. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. PMID: 17241515.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    95. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006 Oct 01; 24(28):e48. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. PMID: 17008686.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    96. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):214-8. Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV, Lenz HJ. PMID: 17026791.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    97. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ. PMID: 16847424.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    98. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 2006 Feb; 24(1):50-5. El-Khoueiry AB, Lenz HJ. PMID: 16466993.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    99. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. 1995 Feb; 69(2):748-55. Challita PM, Skelton D, el-Khoueiry A, Yu XJ, Weinberg K, Kohn DB. PMID: 7815539; PMCID: PMC188638.
      View in: PubMed   Mentions: 72     Fields:    Translation:AnimalsCells